Carroll Financial Associates’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | $236K | Sell |
1,010
-143
| -12% | -$36.8K | 0.01% | 361 |
|
|
2021
Q3 | $326K | Sell |
1,153
-274
| -19% | -$89.8K | 0.02% | 307 |
|
|
2021
Q2 | $494K | Buy |
1,427
+211
| +17% | +$63.9K | 0.03% | 258 |
|
|
2021
Q1 | $340K | Buy |
1,216
+200
| +20% | +$53.9K | 0.02% | 294 |
|
|
2020
Q4 | $248K | Hold |
1,016
| – | – | 0.02% | 327 |
|
|
2020
Q3 | $288K | Buy |
1,016
+72
| +8% | +$20.1K | 0.02% | 285 |
|
|
2020
Q2 | $252K | Buy |
944
+501
| +113% | +$151K | 0.02% | 301 |
|
|
2020
Q1 | $140K | Hold |
443
| – | – | 0.01% | 359 |
|
|
2019
Q4 | $131K | Sell |
443
-12
| -3% | -$3.33K | 0.01% | 447 |
|
|
2019
Q3 | $105K | Sell |
455
-6
| -1% | -$1.4K | 0.01% | 497 |
|
|
2019
Q2 | $107K | Sell |
461
-36
| -7% | -$8.31K | 0.01% | 487 |
|
|
2019
Q1 | $117K | Sell |
497
-34
| -6% | -$10.7K | 0.01% | 408 |
|
|
2018
Q4 | $171K | Buy |
531
+12
| +2% | +$3.83K | 0.02% | 291 |
|
|
2018
Q3 | $183K | Buy |
519
+4
| +0.8% | +$1.38K | 0.02% | 298 |
|
|
2018
Q2 | $149K | Buy |
515
+19
| +4% | +$5.34K | 0.02% | 316 |
|
|
2018
Q1 | $135K | Hold |
496
| – | – | 0.01% | 329 |
|
|
2017
Q4 | $158K | Hold |
496
| – | – | 0.02% | 300 |
|
|
2017
Q3 | $162K | Hold |
496
| – | – | 0.02% | 297 |
|
|
2017
Q2 | $134K | Buy |
496
+6
| +1% | +$1.59K | 0.02% | 321 |
|
|
2017
Q1 | $133K | Hold |
490
| – | – | 0.02% | 309 |
|
|
2016
Q4 | $138K | Hold |
490
| – | – | 0.02% | 294 |
|
|
2016
Q3 | $153K | Hold |
490
| – | – | 0.02% | 277 |
|
|
2016
Q2 | $118K | Hold |
490
| – | – | 0.02% | 309 |
|
|
2016
Q1 | $127K | Buy |
490
+18
| +4% | +$4.75K | 0.02% | 280 |
|
|
2015
Q4 | $144K | Sell |
472
-208
| -31% | -$59.8K | 0.03% | 239 |
|
|
2015
Q3 | $187K | Sell |
680
-27
| -4% | -$8.92K | 0.04% | 205 |
|
|
2015
Q2 | $286K | Buy |
707
+142
| +25% | +$57K | 0.06% | 154 |
|
|
2015
Q1 | $239K | Buy |
565
+200
| +55% | +$78.8K | 0.11% | 119 |
|
|
2014
Q4 | $143K | Buy |
365
+134
| +58% | +$43.4K | 0.09% | 131 |
|
|
2014
Q3 | $74K | Hold |
231
| – | – | 0.02% | 255 |
|
|
2014
Q2 | $73K | Buy |
231
+16
| +7% | +$4.82K | 0.02% | 262 |
|
|
2014
Q1 | $66K | Buy |
215
+46
| +27% | +$14.6K | 0.02% | 258 |
|
|
2013
Q4 | $47K | Hold |
169
| – | – | 0.02% | 293 |
|
|
2013
Q3 | $40K | Buy |
169
+64
| +61% | +$14.3K | 0.02% | 317 |
|
|
2013
Q2 | $22K | Buy |
+105
| New | +$22.4K | 0.01% | 317 |
|
Other funds holding BIIB
Carroll Financial Associates's BIIB Position: Q4 2021 in Review
Carroll Financial Associates reduced its Biogen (BIIB) stake by 12% in Q4 2021, selling an estimated $36.8K and leaving 1,010 shares worth $236K. The position accounts for 0.01% of the portfolio, ranked #361.
Carroll Financial Associates first reported a position in BIIB in Q2 2013 and has held it in 35 quarters since. The position peaked at $494K in Q2 2021. 1,009 funds tracked by Wall St. Rank hold BIIB as of Q4 2021.
- Carroll Financial Associates held 1,010 shares of Biogen worth $236K as of Q4 2021.
- Carroll Financial Associates sold 143 Biogen shares in Q4 2021, an estimated $36.8K.
- Biogen made up 0.01% of Carroll Financial Associates's portfolio in Q4 2021, its #361 holding.
- Carroll Financial Associates first reported a position in Biogen in Q2 2013 and has held it in 35 quarters since.
- Carroll Financial Associates's Biogen position peaked at $494K in Q2 2021.
- 1,009 funds tracked by Wall St. Rank held Biogen as of Q4 2021.
Based on Carroll Financial Associates's 13F filing for Q4 2021, filed 6 Jan 2022.